Vertex Pharmaceuticals plans to conclude the enrollment of patients in its Phase 3 programs involving its triple combo therapies to treat cystic fibrosis (CF) in the second half of 2018, the company recently announced in a corporate update. This is earlier than expected for the four Phase 3 trials, which are testing triple combinations of VX-661 (tezacaftor) and […]
The post Vertex Anticipates Completing Enrollment of Phase 3 Trials Testing Triple Combo Therapies appeared first on Cystic Fibrosis News Today. |
No hay comentarios:
Publicar un comentario